Identifying prognostic and predictive value of mutations associated with clinical outcomes in first line (1L) patients with advanced or metastatic non-small cell lung cancer (aNSCLC).

被引：0
|
作者：
Perez Parente, Diego
Cobo-Dols, Manuel
Hasan, Haroon
Olson, Sara
Pal, Navdeep
Wilkinson, Samantha
La Orden Tevar, Beatriz
Perez Fernandez, Mar
Provencio-Pulla, Mariano
机构：
[1] Roche Farma, Lung Canc Squad, Madrid, Spain
[2] Hosp Univ Reg Malaga, Malaga, Spain
[3] Genentech Inc, Product Dev Data Sci, San Francisco, CA USA
[4] Roche Prod Ltd, Welwyn Garden City, Herts, England
[5] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9047
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
    Prelaj, A.
    Rebuzzi, S. E.
    Pizzutilo, P.
    Bilancia, M.
    Montrone, M.
    Pesola, F.
    Longo, V.
    Del Bene, G.
    Lapadula, V.
    Cassano, F.
    Petrillo, P.
    Bafunno, D.
    Varesano, N.
    Lamorgese, V.
    Mastranrdea, A.
    Ricci, D.
    Catino, A.
    Galetta, D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer
    Stokke, Kristin
    Sandvei, Marie Softeland
    Gronberg, Bjorn Henning
    Slaaen, Marit
    Killingberg, Kristin T.
    Halvorsen, Tarje O.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [33] Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer
    Stokke, Kristin
    Sandvei, Marie Softeland
    Gronberg, Bjorn Henning
    Slaaen, Marit
    Killingberg, Kristin T.
    Halvorsen, Tarje O.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [34] Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany
    Snee, M.
    Cheeseman, S.
    Levick, B.
    Hall, G.
    Rohde, G.
    Stratmann, J.
    Wolf, A.
    van Gils, C.
    Griner, R.
    Mahmood, A.
    Niklas, N.
    Divan, H. A.
    Krishna, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S52 - S53
  • [35] NETWORK META-ANALYSIS DESIGN CONSIDERATIONS IN A COMPLEX AND RAPIDLY EVOLVING LANDSCAPE: A CASE STUDY IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
    Popoff, E.
    Lozano-Ortega, G.
    Varol, N.
    Yuan, Y.
    Penrod, J. R.
    Goring, S. M.
    VALUE IN HEALTH, 2020, 23 : S471 - S471
  • [36] First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)
    Lorenzi, M.
    Dal Maso, A.
    Ferro, A.
    Polo, V.
    Scattolin, D.
    Macerelli, M.
    Follador, A.
    Targato, G.
    Indraccolo, S.
    Frega, S.
    Menis, J.
    Bonanno, L.
    Guarneri, V.
    Conte, P. F.
    Pasello, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S779
  • [37] PROGNOSTIC SIGNIFICANCE, ACCURACY AND USEFULNESS OF ONCOLOGISTS ESTIMATES OF SURVIVAL TIME FOR PATIENTS STARTING FIRST LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
    Kiely, Belinda E.
    Veillard, Anne-Sophie
    Davidson, John A.
    Trinkaus, Mateya E.
    Briscoe, Karen P.
    Hughes, Brett G. M.
    Begbie, Stephen
    Pavlakis, Nick
    Millward, Michael
    Boyer, Michael
    Brown, Chris
    Muljadi, Nick
    Coskinas, Xanthi
    Stockler, Martin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 75 - 75
  • [38] Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation
    Bondarenko, I.
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    ANNALS OF ONCOLOGY, 2022, 33 : S84 - S85
  • [39] Evaluation of the prognostic/predictive role of tumor EGFR and KRAS mutations in Greek metastatic non-small cell lung cancer patients treated with first-line chemotherapy
    Linardou, Helena
    Kosmidis, Paris A.
    Kotoula, Vassiliki
    Karavasilis, Vasilios
    Eleftheraki, Anastasia G.
    Lazaridis, Georgios
    Daskalaki, Emily
    Lakis, Sotiris
    Charalambous, Elpida
    Samantas, Epaminontas
    Pectasides, Dimitrios G.
    Bafaloukos, Dimitris
    Fountzilas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer
    Zhang, Yuepeng
    Mi, Kai
    Li, Zhiheng
    Qiang, Lixia
    Lv, Meiyu
    Wu, Yushan
    Yuan, Ligong
    Jin, Shoude
    FRONTIERS IN ONCOLOGY, 2021, 11
12345